Presentation Slides with Audio

Chairs: Viktor Grünwald, MD, PhD and Lisa DeRosa, MD, PhD

Abstract Awards Presentation: Viktor Grünwald, MD, PhD

ORAL ABSTRACT 1: A Biomarker Analysis of Tide-A, a Phase 2 Study of First-Line Avelumab Plus Intermittent Axitinib: Circulating Kidney Injury Molecule-1 (KIM-1) in mRCC: Romina Rose Pedone

Presentation

ORAL ABSTRACT 2: Subgroup Analyses of Health-Related Quality of Life (HRQoL) Outcomes in the Phase 3 CLEAR Trial: Thomas Powles, MBBS, MRCP, MD

Presentation

ORAL ABSTRACT 3: The Importance of Multidisciplinary Team Meetings (MDMs) with Focus on Minimal Surgery: Lars Lund, DMSci, FCS(HK)

Presentation

ORAL ABSTRACT 4: Genomic Profiling of Non-Clear Cell Renal Cell Carcinoma: Insights for Prognosis and Treatment: Mimma Rizzo

Presentation

Session 6 Q&A: Viktor Grünwald, MD, PhD and Lisa DeRosa, MD, PhD

POSTER AD 1: A phase III Study Testing the Role of Proactive Coaching on Patient Reported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated with Sunitinib or a Combination of Axitinib + Pembrolizumab or Avelumab in First Line Therapy (PREPARE; AIO-NZK-011: Viktor Grünwald, MD, PhD

Presentation

POSTER AD 2: How Different are the Expression Levels of Immune Checkpoint Molecules and TTheir Roles on the Prognosis in Surgically Treated Non-Metastatic Clear Cell, Papillary, and Chromophobe Subtypes of Renal Cell Carcinoma?: Selcuk Erdem

Presentation

POSTER AD 3: Comparison of IO-TKI vs IO-IO Combinations in IMDC Poor-Risk Metastatic Renal Cell Carcinoma (mRCC) Patients (Meet-URO 33 Analysis): Davide Bimbatti

Presentation

POSTER AD 4: Two-Stage Estimation of Overall Survival (OS) in CheckMate 9ER (CM9ER), Adjusting for the Impact of Subsequent Therapy: Emma Karim

Presentation

POSTER AD 5: CABONEXT: CABONEXT: Advanced Renal Cell Carcinoma Treatment Following Cabozantinib: A Retrospective Analysis of Sequencing Therapies: Simon Nannini

Presentation